Intended for healthcare professionals


NICE approves taxanes for breast cancer

BMJ 2000; 320 doi: (Published 24 June 2000) Cite this as: BMJ 2000;320:1688
  1. Caroline White
  1. London

    The National Institute for Clinical Excellence (NICE) last week approved the use of taxanes for the treatment of advanced breast cancer for women in England and Wales.

    A course of treatment will cost around £1500 ($2250) and is expected to add £16m to the NHS annual drugs bill. Last month the Department of Health asked the …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription